The Traderszone Network

Published in TZ Latest News 3 July, 2021 by The TZ Newswire Staff

ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer

— ORR of 72% Observed in Patients with >2L HER2 Positive Gastric or Gastroesophageal Junction Cancer 
— Estimated OS at 12 months of 76% 
— ALX Oncology to Host Conference Call on July 6th at 8:30 a.m. ET